Try our Advanced Search for more refined results

In re ACTOS Antitrust Litigation

  1. September 30, 2024

    Takeda End Payors, Direct Buyers Win Antitrust Class Cert.

    A New York federal judge Monday adopted a magistrate judge's recommendation to certify two classes of direct purchasers and end payors in consolidated antitrust actions accusing Takeda Pharmaceuticals Co. of unlawfully inflating the price of its diabetes treatment Actos by delaying entry of generic alternatives.

  2. August 09, 2024

    Takeda Should Face Certified Antitrust Classes, Judge Says

    A New York federal judge on Friday recommended certifying two classes of direct purchasers and end payors in consolidated antitrust actions accusing Takeda Pharmaceuticals Co. of unlawfully inflating the price of its diabetes treatment Actos by delaying entry of generic alternatives.

  3. January 29, 2020

    Takeda Gets Go-Ahead To Appeal Actos Rulings At 2nd Circ.

    A New York federal judge has given pharmaceutical firm Takeda permission to appeal to the Second Circuit two decisions that preserved allegations it delayed the entry of generic alternatives to diabetes treatment Actos.

  4. October 23, 2018

    Takeda Tries Again To Shake Actos Antitrust Claims

    Takeda Pharmaceutical Co. told a New York federal judge Tuesday that it's common practice for drugmakers to draw loose connections between their products and their intellectual property in a national register of government-approved drugs, arguing that an antitrust lawsuit allegedly painting that list as scripture should be dismissed for a second time.

  5. October 22, 2015

    Actos Buyers Head To 2nd Circ. After Pay-For-Delay Suit Nixed

    Buyers of the diabetes drug Actos on Thursday told a New York federal judge, who last month dismissed their pay-for-delay suit against Takeda and five generic drugmakers, that they are appealing his decision to the Second Circuit.

  6. September 23, 2015

    Actos Pay-For-Delay Class Action Gets The Boot

    Takeda and five generic-drug makers escaped a pay-for-delay suit over the diabetes drug Actos when a New York federal judge ruled Tuesday that drug buyers relied on too broad an interpretation of the U.S. Supreme Court's decision in Federal Trade Commission v. Actavis Inc.

  7. July 27, 2015

    Drug Cos. Say Rulings Don't Boost Actos Pay-For-Delay Suit

    Three recent high-profile antitrust rulings should have no bearing on a pay-for-delay suit over Takeda Pharmaceutical Co.'s diabetes drug Actos, the defendants told a New York federal judge Friday, disputing plaintiffs' suggestion that the appellate decisions bolster their argument.

  8. June 05, 2015

    Calif. Ruling Backs Actos Pay-For-Delay Suit, Buyers Say

    End-payor plaintiffs accusing Takeda Pharmaceutical Co. and other drugmakers of participating in a pay-for-delay scheme over diabetes drug Actos told a New York federal court Thursday that a recent California Supreme Court ruling in another pay-for-delay case bolsters their argument against the dismissal of their allegations.

  9. May 20, 2015

    FTC's Abbvie Loss Doesn't Apply To Actos Case, Court Told

    The plaintiffs accusing Takeda Pharmaceutical Co. and other drugmakers of participating in a pay-for-delay scheme for the Actos diabetes drug argued Tuesday in New York federal court that a recent high-profile ruling against the Federal Trade Commission in a similar filing should not have any bearing on the case.

  10. May 13, 2015

    Takeda Says FTC's AbbVie Loss Backs Actos Dismissal Bid

    Takeda Pharmaceutical Co. Ltd. and several generic-drug makers accused of delaying cheaper versions of diabetes treatment Actos on Tuesday said the recent dismissal of a chunk of one of the Federal Trade Commission's own pay-for-delay cases has doomed the Actos antitrust litigation.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!